-
1
-
-
0028021968
-
Peripheral and central trigeminovascular activation in cat is blocked by the novel serotonin (5-HT)-lD agonist 31 1C90
-
Goadsby PJ, Edvinsson L: Peripheral and central trigeminovascular activation in cat is blocked by the novel serotonin (5-HT)-lD agonist 31 1C90. Headache 1994;34:394-399.
-
(1994)
Headache
, vol.34
, pp. 394-399
-
-
Goadsby, P.J.1
Edvinsson, L.2
-
2
-
-
0005327707
-
Preclinical and eiinical pharmacology of the novel antimigraine compound. 31 1C90
-
Martin GR, Dixon RM: Preclinical and eiinical pharmacology of the novel antimigraine compound. 31 1C90. Headache 1995:35:291.
-
(1995)
Headache
, vol.35
, pp. 291
-
-
Martin, G.R.1
Dixon, R.M.2
-
3
-
-
0343131203
-
Similar pharmacokinetics and tolera-bility of the novel antimigraine compound 311C90 in young and elderly volunteers
-
Seaber E, On N, Jackson S, Dixon R, Watt H, Posner J: Similar pharmacokinetics and tolera-bility of the novel antimigraine compound 311C90 in young and elderly volunteers. Cephalalgia 1995; 15(suppl 14):216.
-
(1995)
Cephalalgia
, vol.15
, pp. 216
-
-
Seaber, E.1
On, N.2
Jackson, S.3
Dixon, R.4
Watt, H.5
Posner, J.6
-
4
-
-
0001572202
-
A multicenter, double-blind, placebo-controlled study to investigate the efficacy and safety of oral doses of 3I1C90 in the acute treatment of migraine
-
Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM: A multicenter, double-blind, placebo-controlled study to investigate the efficacy and safety of oral doses of 3I1C90 in the acute treatment of migraine. Headache. 1995:35: 292.
-
(1995)
Headache
, vol.35
, pp. 292
-
-
Dahlof, C.1
Diener, H.C.2
Goadsby, P.J.3
Massiou, H.4
Olesen, J.5
Schoenen, J.6
Wilkinson, M.7
Sweet, R.M.8
-
5
-
-
0029926020
-
311C90. A new central and peripherally acting 5-HTID receptor agonist in the acute oral treatment of migraine: A double blind, placebo controlled, dose range finding study
-
Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD: 311C90. a new central and peripherally acting 5-HTID receptor agonist in the acute oral treatment of migraine: a double blind, placebo controlled, dose range finding study. Neurology 1996:46:522-526.
-
(1996)
Neurology
, vol.46
, pp. 522-526
-
-
Visser, W.H.1
Klein, K.B.2
Cox, R.C.3
Jones, D.4
Ferrari, M.D.5
-
6
-
-
0343438148
-
Brown DL for the US 311C90 Dose Ranging Study Group: Optimizing the oral dose of 3IIC90 in the acute treatment of migraine
-
Rapoport AM, Cady RK, Matthew NT, Ramadan NM, Taylor FR, Saper JR, Earl NL, Brown DL for the US 311C90 Dose Ranging Study Group: Optimizing the oral dose of 3IIC90 in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14):221.
-
(1995)
Cephalalgia
, vol.15
, pp. 221
-
-
Rapoport, A.M.1
Cady, R.K.2
Matthew, N.T.3
Ramadan, N.M.4
Taylor, F.R.5
Saper, J.R.6
Earl, N.L.7
-
7
-
-
0013512772
-
311C90. A new acute treatment for migraine: An efficacy overview
-
Klein KB: 311C90. a new acute treatment for migraine: an efficacy overview. Cephalalgia 1995; 15(suppl 14): 175.
-
(1995)
Cephalalgia
, vol.15
, pp. 175
-
-
Klein, K.B.1
-
8
-
-
0346031709
-
Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain
-
Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia. 1988;8(suppl 7): 1-96.
-
(1988)
Cephalalgia
, vol.8
, pp. 1-96
-
-
-
9
-
-
0344003362
-
31IC90. A new acute treatment for migraine: An overview of safety
-
Earl NL: 31IC90. a new acute treatment for migraine: an overview of safety. Cephalalgia 1995;15(suppl 14):217.
-
(1995)
Cephalalgia
, vol.15
, pp. 217
-
-
Earl, N.L.1
|